iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Arcturus Therapeutics

Marinus Pharmaceuticals

This can happen when a company holds out its hand for a big chunk of fresh capital.

Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday

Cantel Medical

Sutro Biopharma Inc

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why iBio, Sutro And Cantel Medical Are Moving Today

Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.

A Lack of Progress Keeps IBIO Shares As a Sell

The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.

Firming Financials Point to an Underappreciation of iBio Stock

BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. The offering is expected to close on or about December 10, 2020, subject to customary closing conditions. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock.

iBio Announces Pricing of $35 Million Public Offering of Common Stock

While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs. The post Why iBio Remains Worth a Look In a Post-Pandemic Landscape appeared first on InvestorPlace.

Why iBio Remains Worth a Look In a Post-Pandemic Landscape

BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten public offering of its common stock. In addition, iBio has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

iBio Announces Proposed Public Offering of Common Stock

Biotech innovator IBIO stock has been tossed around based on iBio's COVID-19 vaccine progress, but its FastPharma tech is the long-term play. The post Biotech Innovator IBIO Is Down, but Not Out for the Long Term appeared first on InvestorPlace.

Biotech Innovator IBIO Is Down, but Not Out for the Long Term

Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company. The post iBio News: Why IBIO Stock Is Soaring 16% Today appeared first on InvestorPlace.

iBio News: Why IBIO Stock Is Soaring 16% Today

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio's FastPharming ® System.

iBio Selected to Produce ATB Therapeutics' Bioengineered Antibody-Toxin Fusion Proteins

iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.

The Case for iBio Stock Is Real, but Leaves a Key Question Unanswered

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of nearly 817 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has the potential to beat the market over the long-term. Therefore, let's take a closer look at what smart money thinks about iBio, Inc. (NYSE:IBIO).

Is iBio, Inc. (IBIO) A Good Stock To Buy?

One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.

It's Time for iBio Speculators to Consider Something Else

- Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic Development Program - - Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic Development Program -

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here's the latest on IBIO stock.

iBio Looks Well-Positioned to Succeed

iBio's first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.

Why iBio Presents a Dilemma to Shareholders

The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.

Stay Away From iBio, Which Constantly Issues Shares to Survive

iBio, Inc. (iBio) CEO Thomas Isett on Q1 2021 Results - Earnings Call Transcript

BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30, 2020.

iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update

The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.

Up 600% Year-to-Date, Sell iBio Stock While It's Still Flying High

iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders. The post Two Covid-19 Vaccine Candidates Hold Promise for iBio appeared first on InvestorPlace.

Two Covid-19 Vaccine Candidates Hold Promise for iBio

Investor interest a unique production system isn't enough to make buying IBIO stock a worthwhile move at this time. The post iBio Remains a Biotech Sideline Play as Covid Rages appeared first on InvestorPlace.

iBio Remains a Biotech Sideline Play as Covid Rages

BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results after market close on Monday, November 16, 2020. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020

IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that's a simplistic view of iBio's prospects. The post First to COVID-19 Vaccine or Not, iBio Is a Smart Investment appeared first on InvestorPlace.

First to COVID-19 Vaccine or Not, iBio Is a Smart Investment

- Brings >20 Years of Global Biotech Operations and Business Development Experience - - Brings >20 Years of Global Biotech Operations and Business Development Experience -

News for iBio Stock (IBIO)